Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Edurne Arriola"'
Autor:
Esther Conde, MD, PhD, Susana Hernandez, PhD, Jose Luis Rodriguez Carrillo, MD, Rebeca Martinez, APT, Marta Alonso, APT, Daniel Curto, MD, Beatriz Jimenez, MD, Alejandra Caminoa, MD, PhD, Amparo Benito, MD, Pilar Garrido, MD, PhD, Sergi Clave, PhD, Edurne Arriola, MD, PhD, Isabel Esteban-Rodriguez, MD, PhD, Javier De Castro, MD, PhD, Irene Sansano, MD, Enriqueta Felip, MD, PhD, Federico Rojo, MD, PhD, Manuel Dómine, MD, PhD, Ihab Abdulkader, MD, PhD, Jorge Garcia-Gonzalez, MD, Cristina Teixido, PhD, Noemi Reguart, MD, PhD, Desamparados Compañ, MD, PhD, Amelia Insa, MD, Nuria Mancheño, MD, PhD, Sarai Palanca, MD, PhD, Oscar Juan-Vidal, MD, PhD, Nuria Baixeras, MD, Ernest Nadal, MD, PhD, Maria Cebollero, MD, Antonio Calles, MD, Paloma Martin, MD, PhD, Clara Salas, MD, PhD, Mariano Provencio, MD, PhD, Ignacio Aranda, MD, PhD, Bartomeu Massuti, MD, Laura Lopez-Vilaro, MD, Margarita Majem, MD, PhD, Luis Paz-Ares, MD, PhD, Fernando Lopez-Rios, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100653- (2024)
Introduction: RET inhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RET fusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencin
Externí odkaz:
https://doaj.org/article/a3e58ca9d39948fda3972ff1d75a8f34
Autor:
Sergi Clavé, Jennifer B. Jackson, Marta Salido, Jacob Kames, Kelly M. R. Gerding, Ellen L. Verner, Eric F. Kong, Elizabeth Weingartner, Joan Gibert, Max Hardy-Werbin, Pedro Rocha, Xènia Riera, Erica Torres, James Hernandez, Gustavo Cerqueira, Donna Nichol, John Simmons, Álvaro Taus, Lara Pijuan, Beatriz Bellosillo, Edurne Arriola
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionNext-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the better characterization of a tumor’s molecular landscape. However, further e
Externí odkaz:
https://doaj.org/article/80540fee92c8444d8cf2e823ff47914c
Autor:
Alejandro Rios-Hoyo, Edurne Arriola
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Brain metastases (BMs) are the most common form of intracranial malignant neoplasms in adults, with a profound impact on quality of life and traditionally associated with a dismal prognosis. Lung cancer accounts for approximately 40%–50% of BM acro
Externí odkaz:
https://doaj.org/article/7edb4911101e4fe4889b4a629e414170
Autor:
Claire Olingy, Ahmad Alimadadi, Daniel J. Araujo, David Barry, Norma A. Gutierrez, Max Hardy Werbin, Edurne Arriola, Sandip Pravin Patel, Christian H. Ottensmeier, Huy Q. Dinh, Catherine C. Hedrick
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths globally. Immune checkpoint blockade (ICB) has transformed cancer medicine, with anti-programmed cell death protein 1 (anti-PD-1) therapy now well-utilized for treati
Externí odkaz:
https://doaj.org/article/1269b37320e04f1fb1151f73ee5673c6
Autor:
Edurne Arriola, MD, PhD, José Manuel Trigo, MD, Amparo Sánchez-Gastaldo, MD, Alejandro Navarro, MD, Coral Perez, MD, Leonardo Crama, MD, Santiago Ponce-Aix, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100266- (2022)
Introduction: SCLC is one of the most lethal malignancies. Classically, staging has been performed using a dual classification distinguishing limited from the extensive stage. This study aimed to evaluate the prognostic value of TNM staging in a real
Externí odkaz:
https://doaj.org/article/ee4d170a7bb04b6b9b63698467121349
Publikováno v:
Cancers, Vol 14, Iss 8, p 1931 (2022)
EGFR-mutated tumors represent a significant percentage of non-small cell lung cancer. Despite the increasing use of osimertinib, a treatment that has demonstrated an outstanding clinical benefit with a tolerable toxicity profile, EGFR tumors eventual
Externí odkaz:
https://doaj.org/article/9d4975ff07dc4a889b2fb3d76391740a
Autor:
Pedro Rocha, MD, Didac Ramal, MD, Enric Ripoll, MD, Laura Moliner, MD, Alex Corbera, MD, Max Hardy-Werbin, MD, PhD, Mayra Orrillo, MD, Álvaro Taus, MD, Flavio Zuccarino, MD, Joan Gibert, Júlia Perera-Bel, David Casadevall, MD, PhD, Edurne Arriola, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100115- (2021)
Introduction: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different ass
Externí odkaz:
https://doaj.org/article/aa5ac2c35017431287482d1faf250d70
Autor:
Emmett Schmidt, Jonathan Thompson, Michael Chisamore, James Spicer, Åslaug Helland, Edurne Arriola, Manuel Dómine Gomez, Jose Manuel Trigo Perez, Ana Laura Ortega Granados, Noelly Madeleine, Austin Rayford, Katherine Lorens, Abdul Siddiqui, Hani Gabra, Jaya Nautiyal, David Micklem, James Lorens
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/ae2b9c922e2e4cff96ff5a8879f3632b
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100070- (2020)
Externí odkaz:
https://doaj.org/article/9212eccff4574b62a43dc274e1b4a782
Autor:
Edurne Arriola, Ramón García Gómez, Pilar Diz, Margarita Majem, Maite Martínez Aguillo, Javier Valdivia, Alfredo Paredes, José Miguel Sánchez-Torres, Sergio Peralta Muñoz, Isidoro Barneto, Vanesa Gutierrez, Jesús Manuel Andrade Santiago, Francisco Aparisi, Dolores Isla, Santiago Ponce, David Vicente Baz, Angel Artal, Mariluz Amador, Mariano Provencio
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optima
Externí odkaz:
https://doaj.org/article/5d99fbd38d4248848d0a056c93027a23